Select the histological grade to visualize the international consensus management pathway.
Guidelines & Evidence
Clinical Details
Section 1
When to Use
When to Use
Pathological reporting of mucosal biopsies from the GI tract (especially Barrett's oesophagus and gastric/colorectal polyps)
To standardize the terminology for pre-cancerous and cancerous epithelial lesions
To guide management decisions (Surveillance vs. Endoscopic therapy vs. Surgery)
Clinical Context
The Revised Vienna Classification (2000) was developed to bridge the gap between Western pathologists (who emphasize invasion) and Eastern pathologists (who emphasize nuclear cytological changes).
Category 5: Invasive neoplasia (Intramucosal or submucosal carcinoma).
Management Implications
Category 1
Repeat surveillance per standard intervals.
Category 2
Repeat biopsy in 3-6 months after PPI optimization.
Category 3
Endoscopic therapy (RFA) or intensive surveillance (6 mo).
Category 4
Endoscopic therapy (EMR/ESD/RFA) or surgical resection.
Category 5
Surgical resection (standard) or ESD (if T1a).
Section 3
Pearls/Pitfalls
Why Category 2 Matters
"Indefinite for Neoplasia" often reflects significant inflammation (e.g., active oesophagitis) that mimics dysplasia. Aggressive acid suppression (high-dose PPI) for 8-12 weeks before re-biopsy is critical to allow these reactive changes to regress.
The Confirmatory Pathology Rule
Current ACG and BSG guidelines mandate that any diagnosis of High-Grade Dysplasia (Category 4) or Low-Grade Dysplasia (Category 3) in Barrett's MUST be confirmed by a second independent expert gastrointestinal pathologist.
Developed during a 1998 meeting in Vienna, where 31 pathologists from 12 countries met to resolve long-standing discrepancies in how pre-malignant lesions were reported globally. This consensus was vital for comparing clinical trial results between Asian and Western centers.
